Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D2.200 - An interim analysis of a multiCenter study on the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders (CALM study)
D2.202 - Evaluation of Telemedicine Use in Dietary Advancement Therapy of Cow’s Milk and Egg Allergy: A Retrospective Study
D2.204 - Allergic potential of plant-derived oils: in vitro murine model of allergies
D2.206 - Successful treatment of LTP syndrome using allergen immunotherapy: a clinical case
D2.378 - Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule
D2.367 - Hepatic Involvement and Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Retrospective Evaluation
D2.368 - Concurrent Hereditary Angioedema Type I and Common Variable Immunodeficiency Presenting as Suspected Antibiotic Hypersensitivity: Case Report and Literature Review
D2.370 - Chronic urticaria and autoimmunity: clinical, laboratory and molecular correlations
D2.374 - Diagnostic delay in children with primary immunodeficiencies: clinical consequences in a single-country cohort from the Republic of Moldova
D2.375 - Structural lung changes detected by chest CT in pediatric patients with combined immunodeficiencies
D2.377 - Severe Eosinophilia as an Atypical Initial Presentation of X-Linked Hyper-IgM Syndrome Due to CD40LG Deficiency
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
Download the app
The congress at your fingertips
Available on
Download